Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting

• IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met
• First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009

Available on line:

• Poster on Phase I trial in Multiple Myeloma (preliminary data)
  
• Poster on Phase I trial in Acute Myeloid Leukemia (preliminary data)